Figure 2.
Quantification of the BRAFV600E mutation in the plasma (A) and serum (B) of advanced stage melanoma patients, expressed in pg of mutated genome/µL of fluid. Patients are classified according to clinical stage.
Quantification of the BRAFV600E mutation in the plasma (A) and serum (B) of advanced stage melanoma patients, expressed in pg of mutated genome/µL of fluid. Patients are classified according to clinical stage.